Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma

This study combines freezing the tumor (cryoablation) with two drugs — tislelizumab (an immunotherapy) and lenvatinib (a targeted therapy) — as a second-line or later treatment for advanced liver cancer (hepatocellular carcinoma) that cannot be surgically removed. **You may be eligible if...** - You have advanced liver cancer (hepatocellular carcinoma) confirmed by biopsy or imaging - Your cancer has progressed or become intolerable on at least one prior treatment regimen - You are 18 or older with adequate organ function and reasonable overall health - You have at least one measurable tumor **You may NOT be eligible if...** - You have not tried any prior systemic treatment for advanced liver cancer - You have severe active autoimmune disease or are on immunosuppressants - You have uncontrolled infections, HIV, or certain other serious conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.